Clinical outcomes of head and neck mucosal melanoma treated with surgery: a single-center study in Japan
Authors:
- Go OmuraGOGo Omura
- Kenjiro NamikawaKNKenjiro Namikawa
- Kohtaro EguchiKEKohtaro Eguchi
- Yoshifumi MatsumotoYMYoshifumi Matsumoto
- Azusa SakaiASAzusa Sakai
- Kenya KobayashiKKKenya Kobayashi
- Eiji NakanoENEiji Nakano
- Dai OgataDODai Ogata
- Fumihiko MatsumotoFMFumihiko Matsumoto
- Taisuke MoriTMTaisuke Mori
- Naoya YamazakiNYNaoya Yamazaki
- 7 August 2023
- journal article
- research article
- Published by Oxford University Press (OUP) in Japanese Journal of Clinical Oncology
- Vol. 53 (11) , 1045-1050
Abstract
Head and neck mucosal melanomas are rare malignancies. Although the prognosis is poor owing to the high incidence of distant metastases, locoregional control remains important. It is difficult to obtain results in a large cohort because of its rarity. This study aimed to elucidate the survival outcomes of patients with head and neck mucosal melanoma treated with surgery in Japan. Patients with head and neck mucosal melanoma who were surgically treated between 2007 and 2021 at the National Cancer Center Hospital were retrospectively analyzed. A total of 47 patients were included in this study. The 5-year overall survival, disease-specific survival, locoregional control and relapse-free survival rates were 42%, 50%, 79% and 13%, respectively. The disease-specific survival of the oral mucosal melanoma group was significantly better than that of the sinonasal mucosal melanoma group (5-year disease-specific survival rate: 70% versus 37%, respectively; P = 0.04). Multivariate analyses revealed that sinonasal mucosal melanoma were independently significant adverse prognostic factor, for overall survival and disease-specific survival. Patients with oral mucosal melanoma patients had a higher incidence of lymph node metastasis than those with sinonasal mucosal melanoma patients (P < 0.0001). This study demonstrated the survival outcomes of the largest cohort of patients with head and neck mucosal melanomas treated surgically at a single institution within the past 20 years in Japan. We found that survival outcomes and incidence of nodal metastases varied by site.Keywords
Funding Information
- Japan Society for the Promotion of Science Grants-in-Aid for Scientific Research (18 K09339)
This publication has 13 references indexed in Scilit:
- Adjuvant Dabrafenib plus Trametinib in Stage IIIBRAF-Mutated MelanomaNew England Journal of Medicine, 2017
- Adjuvant Nivolumab versus Ipilimumab in Resected Stage III or IV MelanomaNew England Journal of Medicine, 2017
- Multicenter Study of Carbon-Ion Radiation Therapy for Mucosal Melanoma of the Head and Neck: Subanalysis of the Japan Carbon-Ion Radiation Oncology Study Group (J-CROS) Study (1402 HN)International Journal of Radiation Oncology - Biology - Physics (IJROBP), 2017
- Phase II study of proton beam therapy as a nonsurgical approach for mucosal melanoma of the nasal cavity or para-nasal sinusesRadiotherapy and Oncology, 2016
- Improved Overall Survival in Melanoma with Combined Dabrafenib and TrametinibNew England Journal of Medicine, 2015
- Update on primary head and neck mucosal melanomaHead & Neck, 2014
- Investigation of the freely available easy-to-use software ‘EZR’ for medical statisticsBone Marrow Transplantation, 2012
- Sinonasal mucosal melanoma: Molecular profile and therapeutic implications from a series of 32 casesHead & Neck, 2012
- Primary mucosal malignant melanoma of the head and neckHead & Neck, 2002
- The National Cancer Data Base report on cutaneous and noncutaneous melanomaCancer, 1998